JP2011529037A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011529037A5 JP2011529037A5 JP2011519241A JP2011519241A JP2011529037A5 JP 2011529037 A5 JP2011529037 A5 JP 2011529037A5 JP 2011519241 A JP2011519241 A JP 2011519241A JP 2011519241 A JP2011519241 A JP 2011519241A JP 2011529037 A5 JP2011529037 A5 JP 2011529037A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- carbon atoms
- alkyl
- groups
- prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 125000004432 carbon atom Chemical group C* 0.000 claims 24
- 125000001424 substituent group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 229940002612 prodrug Drugs 0.000 claims 14
- 239000000651 prodrug Substances 0.000 claims 14
- -1 monoalkylamino group Chemical group 0.000 claims 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 6
- 125000003277 amino group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000004442 acylamino group Chemical group 0.000 claims 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 5
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 4
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 4
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 239000002464 receptor antagonist Substances 0.000 claims 3
- 229940044551 receptor antagonist Drugs 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 108090000312 Calcium Channels Proteins 0.000 claims 2
- 102000003922 Calcium Channels Human genes 0.000 claims 2
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 claims 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 2
- 102100034354 Potassium voltage-gated channel subfamily KQT member 2 Human genes 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 2
- 125000003827 glycol group Chemical group 0.000 claims 2
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 229920001515 polyalkylene glycol Polymers 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- OGCMQEYJLBFBKZ-UHFFFAOYSA-N 2-[4-[2,6-dichloro-4-(trifluoromethoxy)anilino]phenyl]-n-(2-hydroxyethyl)acetamide Chemical compound C1=CC(CC(=O)NCCO)=CC=C1NC1=C(Cl)C=C(OC(F)(F)F)C=C1Cl OGCMQEYJLBFBKZ-UHFFFAOYSA-N 0.000 claims 1
- GQLSABOKEQDLSD-UHFFFAOYSA-N 2-[4-[2,6-dichloro-4-(trifluoromethyl)anilino]phenyl]-n-(2-hydroxyethyl)acetamide Chemical compound C1=CC(CC(=O)NCCO)=CC=C1NC1=C(Cl)C=C(C(F)(F)F)C=C1Cl GQLSABOKEQDLSD-UHFFFAOYSA-N 0.000 claims 1
- VXBVFBWALLHUCE-UHFFFAOYSA-N 2-[[2-[4-(3,5-dichloroanilino)phenyl]acetyl]amino]acetic acid Chemical compound C1=CC(CC(=O)NCC(=O)O)=CC=C1NC1=CC(Cl)=CC(Cl)=C1 VXBVFBWALLHUCE-UHFFFAOYSA-N 0.000 claims 1
- SNWSKHQPRZVNIJ-UHFFFAOYSA-N 2-[[2-[5-(3,5-dichloroanilino)-2-fluorophenyl]acetyl]amino]acetic acid Chemical compound C1=C(F)C(CC(=O)NCC(=O)O)=CC(NC=2C=C(Cl)C=C(Cl)C=2)=C1 SNWSKHQPRZVNIJ-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- LEZFMENAFUAIPM-UHFFFAOYSA-N 5-[2,6-dichloro-4-(trifluoromethyl)anilino]-2-fluoro-n-(2-hydroxyethyl)benzamide Chemical compound C1=C(F)C(C(=O)NCCO)=CC(NC=2C(=CC(=CC=2Cl)C(F)(F)F)Cl)=C1 LEZFMENAFUAIPM-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 108091006146 Channels Proteins 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 102000004310 Ion Channels Human genes 0.000 claims 1
- 108090000862 Ion Channels Proteins 0.000 claims 1
- 108010038888 KCNQ3 Potassium Channel Proteins 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010061296 Motor dysfunction Diseases 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 108091008604 NGF receptors Proteins 0.000 claims 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 102100034360 Potassium voltage-gated channel subfamily KQT member 3 Human genes 0.000 claims 1
- 102000002294 Purinergic P2X Receptors Human genes 0.000 claims 1
- 108010000836 Purinergic P2X Receptors Proteins 0.000 claims 1
- 101710084141 Synaptic vesicle glycoprotein 2A Proteins 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 claims 1
- 208000012931 Urologic disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000951 adrenergic alpha-1 receptor antagonist Substances 0.000 claims 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims 1
- 239000003288 aldose reductase inhibitor Substances 0.000 claims 1
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 claims 1
- 229940125681 anticonvulsant agent Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000003420 antiserotonin agent Substances 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 239000000801 calcium channel stimulating agent Substances 0.000 claims 1
- 229940121376 cannabinoid receptor agonist Drugs 0.000 claims 1
- 239000003537 cannabinoid receptor agonist Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229940125400 channel inhibitor Drugs 0.000 claims 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000003149 muscarinic antagonist Substances 0.000 claims 1
- BICBNNOQHPXLSI-UHFFFAOYSA-N n-(2-hydroxyethyl)-2-[3-(2,4,6-trichloroanilino)phenyl]acetamide Chemical compound OCCNC(=O)CC1=CC=CC(NC=2C(=CC(Cl)=CC=2Cl)Cl)=C1 BICBNNOQHPXLSI-UHFFFAOYSA-N 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 239000001301 oxygen Chemical group 0.000 claims 1
- 239000004036 potassium channel stimulating agent Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 229940075993 receptor modulator Drugs 0.000 claims 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 229940125794 sodium channel blocker Drugs 0.000 claims 1
- 239000003195 sodium channel blocking agent Substances 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000009278 visceral effect Effects 0.000 claims 1
- 229940126158 β3 adrenergic receptor agonist Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0813403.3 | 2008-07-22 | ||
| GBGB0813403.3A GB0813403D0 (en) | 2008-07-22 | 2008-07-22 | Potassium ion channel modulators & uses thereof |
| PCT/GB2009/050887 WO2010010380A1 (en) | 2008-07-22 | 2009-07-20 | Potassium ion channel modulators & uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011529037A JP2011529037A (ja) | 2011-12-01 |
| JP2011529037A5 true JP2011529037A5 (enExample) | 2012-06-28 |
Family
ID=39737453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011519241A Pending JP2011529037A (ja) | 2008-07-22 | 2009-07-20 | カリウムイオンチャネル調節剤およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9464052B2 (enExample) |
| EP (1) | EP2310357B1 (enExample) |
| JP (1) | JP2011529037A (enExample) |
| CN (1) | CN102159535A (enExample) |
| DK (1) | DK2310357T3 (enExample) |
| GB (1) | GB0813403D0 (enExample) |
| WO (1) | WO2010010380A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0813403D0 (en) | 2008-07-22 | 2008-08-27 | Lectus Therapeutics Ltd | Potassium ion channel modulators & uses thereof |
| US8624063B2 (en) | 2009-06-30 | 2014-01-07 | Wisconsin Alumni Research Foundation | Non-lactone carbocyclic and heterocyclic antagonists and agonists of bacterial quorum sensing |
| EP2593434A1 (en) | 2010-07-16 | 2013-05-22 | Purdue Pharma LP | Pyridine compounds as sodium channel blockers |
| EP2616441B1 (en) | 2010-09-17 | 2019-08-07 | Purdue Pharma L.P. | Pyridine compounds and the uses thereof |
| KR101599300B1 (ko) * | 2012-03-14 | 2016-03-03 | 시노켐 코포레이션 | 치환 디페닐아민 화합물 및 항종양제로서의 용도 |
| US9206127B2 (en) | 2012-03-16 | 2015-12-08 | Purdue Pharm, L.P. | Substituted pyridines as sodium channel blockers |
| US9714252B2 (en) | 2012-12-20 | 2017-07-25 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
| US10995097B2 (en) * | 2016-03-11 | 2021-05-04 | The Board Of Trustees Of The University Of Illinois | Small molecules active against gram-negative bacteria |
| CN110913689A (zh) * | 2017-05-10 | 2020-03-24 | 罗切斯特大学 | 治疗神经精神病症的方法 |
| CN111433185A (zh) * | 2017-10-09 | 2020-07-17 | 拉莫特特拉维夫大学有限公司 | 钾离子及trpv1通道的调节剂及其用途 |
| US10526278B2 (en) | 2017-10-19 | 2020-01-07 | Wisconsin Alumni Research Foundation | Inhibitors of quorum sensing receptor LasR |
| US20220324809A1 (en) * | 2019-09-03 | 2022-10-13 | Salzman Group Ltd. | Atp-regulated potassium channel openers and uses thereof |
| EP4031548A4 (en) * | 2019-09-17 | 2023-10-18 | Knopp Biosciences LLC | Methods of use for kv7 channel activators |
| TW202237082A (zh) * | 2021-01-22 | 2022-10-01 | 南韓商日東製藥股份有限公司 | 安諾特明６（Ａｎｏｃｔａｍｉｎ ６）之抑制劑及其用途 |
| WO2022175752A1 (en) | 2021-02-19 | 2022-08-25 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| AU2022222470A1 (en) | 2021-02-19 | 2023-09-21 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| KR20230158005A (ko) | 2021-03-18 | 2023-11-17 | 씨젠 인크. | 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출 |
| US20240208896A1 (en) * | 2021-03-19 | 2024-06-27 | Xyzagen, Inc. | Prodrugs of kv7 channel openers |
| KR20240124952A (ko) | 2021-12-22 | 2024-08-19 | 어거스틴 테라퓨틱스 | Hdac6 억제제로서의 화합물 및 이의 용도 |
| WO2023139581A1 (en) * | 2022-01-18 | 2023-07-27 | Bsense Bio Therapeutics Ltd. | Modulators of a potassium channel and of trpv1 channel and uses thereof |
| CN120435316A (zh) * | 2022-08-30 | 2025-08-05 | 拜奥海芬治疗学有限公司 | 包括金属通道激活剂和nmda受体拮抗剂的组合疗法 |
| IT202200024948A1 (it) * | 2022-12-05 | 2024-06-05 | Angelini Pharma S P A | Composti attivatori dei canali potassio KV7.2/KV7.3 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1882286A (en) | 1929-07-17 | 1932-10-11 | Gen Aniline Works Inc | Arylamides of meta-hydroxy-diarylamine-carboxylic acids and process of making same |
| BE590607A (enExample) | 1960-02-24 | |||
| US3413313A (en) | 1964-06-18 | 1968-11-26 | Parke Davis & Co | Anthranilic acid compounds and methods for their production |
| CA1087186A (en) | 1977-01-21 | 1980-10-07 | Kurt H. G. Pilgram | Cycloalkane-carboxanilides |
| US4181519A (en) * | 1977-01-21 | 1980-01-01 | Shell Oil Company | Diphenylamine derivative herbicides |
| ZA865090B (en) | 1985-07-22 | 1988-02-24 | Riker Laboratories Inc | Substituted di-t-butylphenols |
| IL86462A (en) | 1987-05-29 | 1992-12-01 | Fujisawa Pharmaceutical Co | Alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same |
| JPH03278050A (ja) | 1990-03-27 | 1991-12-09 | Konica Corp | ハロゲン化銀写真感光材料 |
| JPH0473190A (ja) | 1990-07-16 | 1992-03-09 | Konica Corp | 感熱転写記録材料 |
| KR950703280A (ko) | 1992-09-09 | 1995-09-20 | 미리암 디.메코너헤이 | 제초성 벤젠 화합물(Herbicidal Benzene Compounds) |
| AU756586C (en) * | 1997-07-01 | 2004-01-29 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| CA2300197A1 (en) | 1997-12-23 | 1999-07-01 | Warner-Lambert Company | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis |
| BR0109188A (pt) * | 2000-03-15 | 2003-03-18 | Warner Lambert Co | Diarilaminas 5-amida substituìdas como inibidores de mex |
| US7001905B2 (en) * | 2000-03-15 | 2006-02-21 | Warner-Lambert Company | Substituted diarylamines as MEK inhibitors |
| FR2836917B1 (fr) * | 2002-03-11 | 2006-02-24 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif |
| JPWO2003082808A1 (ja) * | 2002-04-03 | 2005-08-04 | 住友製薬株式会社 | ベンズアミド誘導体 |
| CA2503075A1 (en) | 2002-10-21 | 2004-04-29 | Ramot At Tel-Aviv University Ltd. | Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators |
| CA2528496C (en) | 2003-06-05 | 2011-04-12 | Elan Pharmaceuticals, Inc. | Acylated amino acid amidyl pyrazoles and related compounds |
| US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| FR2862965B1 (fr) * | 2003-11-27 | 2007-09-07 | Merck Sante Sas | Nouveaux derives de phenoxyacetamides et leur utilisation pour la preparation de diphenylamides. |
| BRPI0519326A2 (pt) | 2004-12-15 | 2009-01-13 | Dompe Pha R Ma Spa Res & Mfg | derivados de Ácido 2-arilpropiânico e composiÇÕes farmacÊuticas contendo-os |
| US8022249B2 (en) | 2005-04-01 | 2011-09-20 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| TWI396543B (zh) | 2005-05-12 | 2013-05-21 | Sankyo Co | 取代丙烯醯胺衍生物及含有它之醫藥組成物 |
| CA2612976C (en) * | 2005-06-21 | 2012-04-10 | Mitsui Chemicals, Inc. | Amide derivative and insecticide containing the same |
| EP1754483A1 (en) | 2005-08-18 | 2007-02-21 | Merck Sante | Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them |
| CN101355939A (zh) | 2005-10-06 | 2009-01-28 | 马萨诸塞大学 | 用于抑制hiv复制的新物质的组合物和合成 |
| GB0813403D0 (en) | 2008-07-22 | 2008-08-27 | Lectus Therapeutics Ltd | Potassium ion channel modulators & uses thereof |
-
2008
- 2008-07-22 GB GBGB0813403.3A patent/GB0813403D0/en not_active Ceased
-
2009
- 2009-07-20 WO PCT/GB2009/050887 patent/WO2010010380A1/en not_active Ceased
- 2009-07-20 JP JP2011519241A patent/JP2011529037A/ja active Pending
- 2009-07-20 EP EP09785362.6A patent/EP2310357B1/en active Active
- 2009-07-20 DK DK09785362T patent/DK2310357T3/da active
- 2009-07-20 CN CN2009801378414A patent/CN102159535A/zh active Pending
- 2009-07-20 US US13/054,960 patent/US9464052B2/en active Active
-
2016
- 2016-09-08 US US15/259,064 patent/US9675567B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011529037A5 (enExample) | ||
| ES2892954T3 (es) | Derivados fluorados del ácido 3-(2-oxo-3-(3-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)propil)imidazolidin-1-il)propanoico y usos de los mismos | |
| RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
| NZ610151A (en) | Salts and crystalline forms of an apoptosis-inducing agent | |
| CA2601508A1 (en) | Cyclopropanecarboxamide derivatives | |
| NZ724602A (en) | Ror-gamma modulators and uses thereof | |
| JP2014502979A5 (enExample) | ||
| NZ708508A (en) | Methods of treatment using selective bcl-2 inhibitors | |
| RU2014115427A (ru) | Фармацевтические композиции замещенных хиназолинонов | |
| NZ603198A (en) | Novel hydroxamic acid derivative | |
| JP2009528296A5 (enExample) | ||
| RU2013108641A (ru) | Способ лечения офтальмологических заболеваний с использованием соединений ингибиторов киназы в пролекарственных формах | |
| JP2013510122A5 (enExample) | ||
| NZ614305A (en) | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | |
| JP2014511892A5 (enExample) | ||
| MX2011013164A (es) | Forma de sosis farmaceutica para administracion oral de un inhibidor de la familia bcl-2. | |
| KR20160060143A (ko) | 히스톤 디아세틸라아제 억제제와 면역조절성 약물의 조합물 | |
| JP2009541443A5 (enExample) | ||
| RU2009118254A (ru) | Фенилацетамиды в качестве ингибиторов протеинкиназ | |
| JP2014525425A5 (enExample) | ||
| NZ612544A (en) | Heterocyclic compounds suitable for the treatment of dyslipidemia | |
| JP2010516701A5 (enExample) | ||
| JP2018048143A5 (enExample) | ||
| CA2554550A1 (en) | Hydroisoindoline tachykinin receptor antagonists | |
| JP2017509694A5 (enExample) |